[A multicenter clinical trial of SMS 201-995 (octreotide acetate) in acromegaly and gigantism].
Sixty-four patients with active acromegaly and three patients with gigantism were treated with the long acting somatostatin analog SMS 201-995 (50-500 micrograms, sc, every 6-12 h or 150-880 micrograms daily by intermittent sc infusion, for up to 114 weeks). The fasting plasma GH levels were significantly suppressed (less than 50% of the values before treatment) in 49 patients and became normal in 18 patients. Suppression of GH secretion was associated with normalization of plasma somatomedin-C levels (14 out of 30 cases) and significant clinical improvement such as disappearance of headache and decrease of excessive sweating. Shrinkage of pituitary tumors as determined by computed tomography and/or magnetic resonance imaging studies occurred in 11 out of 40 cases. Side effects were minimal and tolerable. SMS 201-995 appears to be an effective agent for the treatment of acromegaly and gigantism.
Shimatsu
A
A
Department of Medicine, Kyoto University Faculty of Medicine.
Imura
H
H
Irie
M
M
Nakagawa
S
S
Goto
Y
Y
Shimizu
N
N
Takeda
R
R
Kato
Y
Y
Saito
S
S
Ibayashi
H
H
D000172:Acromegaly / Q000097:blood / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D005260:Female; D005877:Gigantism / Q000097:blood / Q000188:drug therapy*; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D007564:Japan; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D015282:Octreotide / Q000493:pharmacokinetics / Q000627:therapeutic use*
D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D015282:Octreotide